Regencell Bioscience Statistics
Share Statistics
Regencell Bioscience has 13.01M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 13.01M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.24% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 487 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 17.38K, so 0.13% of the outstanding
shares have been sold short.
| Short Interest | 17.38K |
| Short % of Shares Out | 0.13% |
| Short % of Float | 0.72% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -9.71 and the forward
PE ratio is null.
Regencell Bioscience's PEG ratio is
0.36.
| PE Ratio | -9.71 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 5.08 |
| P/FCF Ratio | -10.42 |
| PEG Ratio | 0.36 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Regencell Bioscience.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 41.92,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 41.92 |
| Quick Ratio | 41.92 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-358,486.42 |
| Employee Count | 12 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 3865.83% in the
last 52 weeks. The beta is -4.39, so Regencell Bioscience's
price volatility has been lower than the market average.
| Beta | -4.39 |
| 52-Week Price Change | 3865.83% |
| 50-Day Moving Average | 38.14 |
| 200-Day Moving Average | 14.16 |
| Relative Strength Index (RSI) | 88.39 |
| Average Volume (20 Days) | 708,986 |
Income Statement
| Revenue | n/a |
| Gross Profit | -745.59K |
| Operating Income | -4.74M |
| Net Income | -4.3M |
| EBITDA | -3.62M |
| EBIT | -4.36M |
| Earnings Per Share (EPS) | -0.33 |
Full Income StatementBalance Sheet
The company has 2.96M in cash and 85.74K in
debt, giving a net cash position of 2.88M.
| Cash & Cash Equivalents | 2.96M |
| Total Debt | 85.74K |
| Net Cash | 2.88M |
| Retained Earnings | -21.62M |
| Total Assets | 8.44M |
| Working Capital | 7.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -4M
and capital expenditures -5.38K, giving a free cash flow of -4.01M.
| Operating Cash Flow | -4M |
| Capital Expenditures | -5.38K |
| Free Cash Flow | -4.01M |
| FCF Per Share | -0.31 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
